Simtra BioPharma Solutions cut the ribbon Monday on a new building at its Bloomington campus, capping more than two years of construction on a $250 million expansion that company officials say could potentially double the plant's output of sterile injectable drugs. The new facility sits on the city's west side and adds to Simtra's roughly 600,000-square-foot campus footprint, according to the company.
A Years-Long Build Finally Pays Off
According to Indiana Public Media, construction on the project began in June 2024, and the company says it has created 450 jobs as a result. The new building houses high-speed isolator syringe filling lines and multiple 30-square-meter lyophilizers, or freeze dryers, that are meant to expand Simtra's development of sterile injectable medicines.
As reported by Inside INdiana Business, plans for the expansion were first announced in February 2024, with the company breaking ground the following June. That outlet reports the new 150,000-square-foot building adds two syringe fill lines and one vial fill line to Simtra's existing five commercial lines. Simtra's own facility page describes the addition as a two-story building totaling 153,000 square feet, with 28,000 square feet of classified production space, though the evidence does not clarify whether that figure reflects rounding or a different measurement scope.
The jobs picture has also shifted over time. The same Inside INdiana Business report notes that Simtra originally said the expansion would add 130 jobs, and that an executive, Adams, said the company had already added about 100 jobs through the project before Monday's figure of 450 was announced. The dossier does not reconcile these different counts, which may reflect different time frames or scopes.
Officials Tout Economic Reach
Indiana Gov. Mike Braun spoke before the ribbon cutting, saying the facility's $250 million investment and the hundreds of jobs it represents benefit the community. Bloomington Mayor Kerry Thomson also spoke, saying the expansion's influence stretches beyond city and state lines because medicines made at the facility help patients and families around the world. Thomson added that Bloomington residents and workers who staff the plant help produce therapies that can greatly affect people they will never meet.
Simtra's facility page states that two Bausch + Ströbel prefilled syringe lines with SKAN isolators were slated to become available in 2026, with an isolator-based vial line featuring three lyophilizers planned for 2027, per Simtra BioPharma Solutions. The company has also said the new production lines are being ramped up over the next year amid growing demand for its products.
Why Simtra Is Betting Big on Bloomington
Simtra has framed its Bloomington growth as a response to strong demand signals from customers and what it sees as unmet needs in the U.S. sterile injectable market, according to BioPharm International. The company has already set its sights on further growth nearby: it acquired a 65-acre property with more than 300,000 square feet of available space for future development, saying the move is meant to meet growing global demand for complex, high-value therapies.
The expansion lands amid a broader surge in Indiana's life-sciences sector. The Indiana Business Research Center reports that life-sciences employment in the state rose 12.3% since 2019, even as that growth lagged the national pace, while the sector's real GDP grew 41% in Indiana from 2019 to 2024 compared with 22% nationally. The research center also notes Indiana's average wage in 2024 was $62,727, versus $75,585 nationally, underscoring the stakes of landing high-paying manufacturing jobs like those at Simtra.
Bloomington has seen this kind of expansion promise before, with mixed results. The Herald-Times has reported that Catalent announced a $350 million Bloomington expansion in April 2022 expected to add 1,000 jobs, only to cut positions later that year. Elsewhere in the state, Fishers has also courted biopharma investment: the City of Fishers announced an approximately $200 million expansion for INCOG BioPharma Services in December 2025, saying the company was growing its team to nearly 1,000 employees.
